Plunkett Research Online: Mesoblast Limited

MESOBLAST LIMITED (MESO:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-.....



Mesoblast Limited
Ticker: MESO
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 61 3-9639-6036
Fax: 613 96396030
Address: Level 38, 55 Collins Street
Melbourne, VIC 3000 Australia

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Research and Development in Biotechnology
Biotechnology
Cellular Medicines
Drug Development
Clinical Testing
Contacts Description
Silviu ItescuCEO/Director
Andrew ChaponnelCFO
See More
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-.....See More See More

Auditor: PricewaterhouseCoopers
Legal Advisor:
$USD, In whole numbers,
except marked * or %
202320222021202020192018
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
RYONCIL
REXLEMESTROCEL
NameTitleSalary (AUD)Bonus (AUD)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: